April 20, 2008 |
A cheaper, generic version of GlaxoSmithKline's Wellbutrin XL antidepressant is just as safe and effective as the original drug, despite complaints from some patients, the Food and Drug Administration said. The FDA said it received 85 reports from patients who switched from Wellbutrin XL to a cheaper generic by Teva Pharmaceutical Industries and Impax Laboratories Inc., including 78 who said they slipped back into depression. Agency scientists reviewed versions of the two drugs and found the data did not show the problems stemmed from any differences between them.
March 6, 2007 |
Biovail Corp. reached a settlement with four generic-drug makers that delays sales of cheaper copies of one form of its antidepressant Wellbutrin XL until next year. The deal resolves complaints against Anchen Pharmaceuticals, Impax Laboratories Inc., Teva Pharmaceutical Industries Ltd. and Watson Pharmaceuticals Inc., Mississauga, Canada-based Biovail said Monday. Biovail reported $302.2 million in Wellbutrin XL sales for the first nine months of 2006, or 42% of the company's product revenue.